Vera Therapeutics, Inc. (VERA)
| Market Cap | 1.33B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -175.46M |
| Shares Out | 63.77M |
| EPS (ttm) | -3.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,336,072 |
| Open | 21.16 |
| Previous Close | 21.15 |
| Day's Range | 20.37 - 21.21 |
| 52-Week Range | 18.53 - 51.61 |
| Beta | 1.13 |
| Analysts | Buy |
| Price Target | 64.63 (+208.94%) |
| Earnings Date | Aug 7, 2025 |
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company’s lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for VERA stock is "Buy." The 12-month stock price forecast is $64.63, which is an increase of 208.94% from the latest price.
News
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-...
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments fo...
Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data
Vera Therapeutics, Inc. VERA saw its share price surge over 65% during the pre-market trading session on Monday after the company released ORIGIN Phase 3 trial data.
Vera shares skyrocket as kidney disease drug succeeds in late-stage trial
Shares of Vera Therapeutics soared 82% on Monday, after the company said its experimental drug helped significantly reduce excess levels of harmful proteins in the urine of kidney disease patients in ...
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
BRISBANE, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment ...
Vera Therapeutics: Huge Catalyst Upcoming For Kidney Disease Drug
I am maintaining my 'Hold' rating on Vera Therapeutics from January 2024 despite initial strong stock gains and positive Phase 2b data for atacicept, before a collapse in stock value. In my last note,...
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; planning for Biologics License Application (BLA) submission for ...
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025) U.S. FDA BLA submission for accelerated approval planned for 2H 2025 BRISBANE, Calif., April 03, 2025 (GLOBE NEW...
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
BRISBANE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
BRISBANE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...
Top 3 Health Care Stocks That Could Blast Off This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...
Vera Therapeutics to Participate at Upcoming Investor Conferences
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
BRISBANE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments fo...
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
BRISBANE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments fo...
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years
On Saturday, Vera Therapeutics Inc. VERA released data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy (IgAN), which showed stabilized kidney function through 96 weeks of ...
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
BRISBANE, Calif., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...
Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients
Vera Therapeutics, Inc. topline 36-week data from the phase 3 ORIGIN study, using Atacicept for the treatment of patients with IgA Nephropathy, expected Q2 of 2025. 96-week data from the phase 2 ORIGI...
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
BRISBANE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
BRISBANE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...
Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says
Adobe shares are up 31% over the past three months, having rallied after a strong quarterly earnings report that highlighted strong demand for the software developer's AI products.
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
BRISBANE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...
Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy
Vera Therapeutics is advancing atacicept, a treatment for IgA nephropathy, now in a pivotal Phase 3 trial after promising Phase 2 results. Atacicept has shown potential for significantly reducing prot...
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme...